Skip to content
Menu

Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $22

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $22.

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $22.

Read at benzinga.com